RS51903B - Formulacija aripiprazol kompleksa i postupak - Google Patents

Formulacija aripiprazol kompleksa i postupak

Info

Publication number
RS51903B
RS51903B YU20050118A YUP11805A RS51903B RS 51903 B RS51903 B RS 51903B YU 20050118 A YU20050118 A YU 20050118A YU P11805 A YUP11805 A YU P11805A RS 51903 B RS51903 B RS 51903B
Authority
RS
Serbia
Prior art keywords
complex formulation
aripiprazole
aripiprazole complex
formulation
complex
Prior art date
Application number
YU20050118A
Other languages
English (en)
Inventor
Manoj Nerurkar
Vijay Naringrekar
Mark Dominick
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31946748&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51903(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of RS20050118A publication Critical patent/RS20050118A/sr
Publication of RS51903B publication Critical patent/RS51903B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

FORMULACIJA ARIPIPRAZOL KOMPLEKSA I POSTUPAK. Inkluzioni kompleks aripiprazola u supstituisanom beta-ciklodekstrinu.Prijava sadrži još 19 patentnih zahteva.
YU20050118A 2002-08-20 2003-08-14 Formulacija aripiprazol kompleksa i postupak RS51903B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40471302P 2002-08-20 2002-08-20
PCT/US2003/025573 WO2004017897A2 (en) 2002-08-20 2003-08-14 Aripiprazole complex formulation and method

Publications (2)

Publication Number Publication Date
RS20050118A RS20050118A (en) 2007-06-04
RS51903B true RS51903B (sr) 2012-02-29

Family

ID=31946748

Family Applications (1)

Application Number Title Priority Date Filing Date
YU20050118A RS51903B (sr) 2002-08-20 2003-08-14 Formulacija aripiprazol kompleksa i postupak

Country Status (32)

Country Link
US (8) US7115587B2 (sr)
EP (1) EP1542668B1 (sr)
JP (1) JP4729306B2 (sr)
KR (1) KR101043866B1 (sr)
CN (1) CN100335047C (sr)
AR (2) AR040887A1 (sr)
AT (1) ATE428423T1 (sr)
AU (1) AU2003269965B2 (sr)
BR (1) BR0313602A (sr)
CA (1) CA2495864C (sr)
CY (1) CY1110331T1 (sr)
DE (1) DE60327225D1 (sr)
DK (1) DK1542668T3 (sr)
ES (1) ES2322953T3 (sr)
GE (1) GEP20063996B (sr)
HR (1) HRP20050149B1 (sr)
IL (1) IL166623A (sr)
IS (1) IS2878B (sr)
MX (1) MXPA05001865A (sr)
MY (1) MY140793A (sr)
NO (1) NO333458B1 (sr)
NZ (1) NZ537995A (sr)
PE (1) PE20040895A1 (sr)
PL (1) PL212428B1 (sr)
PT (1) PT1542668E (sr)
RS (1) RS51903B (sr)
RU (1) RU2342931C2 (sr)
SI (1) SI1542668T1 (sr)
TW (1) TWI307626B (sr)
UA (1) UA79984C2 (sr)
WO (1) WO2004017897A2 (sr)
ZA (1) ZA200501064B (sr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040170705A1 (en) * 2001-03-08 2004-09-02 Dusan Miljkovic Compositions and methods for non-insulin glucose uptake
CA2495864C (en) * 2002-08-20 2011-09-27 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
ES2315721T5 (es) * 2003-10-23 2012-08-24 Otsuka Pharmaceutical Co., Ltd. Formulación de aripiprazol inyectable estéril de liberación controlada y procedimiento
US7714129B2 (en) 2003-12-16 2010-05-11 Teva Pharmaceutical Industries Ltd. Methods of preparing anhydrous aripiprazole form II
TW200529850A (en) * 2003-12-16 2005-09-16 Teva Pharma Methods of preparing aripiprazole crystalline forms
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
WO2006113310A2 (en) * 2005-04-13 2006-10-26 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising prostaglandin derivatives
WO2006133046A2 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate imatinib mesylate formulations
US20090036406A1 (en) * 2005-06-13 2009-02-05 Takeda Pharmaceutical Company Limited Injection
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
NZ568700A (en) 2005-11-28 2012-03-30 Marinus Pharmaceuticals Solid stabilized particulate formulations comprising ganaxolone
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
CN101322709B (zh) * 2007-06-12 2011-03-02 成都康弘药业集团股份有限公司 一种含有阿立哌唑的药物组合物及其制备方法
LT2170279T (lt) * 2007-07-31 2018-03-12 Otsuka Pharmaceutical Co., Ltd. Aripiprazolo suspensijos ir liofilizuotos kompozicijos gamybos būdai
US8501740B2 (en) * 2007-10-09 2013-08-06 Board Of Regents, The University Of Texas System Methods of treatment of opioid tolerance, physical dependence, pain and addiction with inhibitors of certain growth factor receptors
EP2268265A2 (en) * 2008-03-21 2011-01-05 Elan Pharma International Limited Compositions for site-specific delivery of imatinib and methods of use
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US8431576B2 (en) 2009-06-25 2013-04-30 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
JP5732453B2 (ja) 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Ｎｈ酸性化合物のプロドラッグ
WO2011023796A1 (en) 2009-08-31 2011-03-03 Abbott Healthcare Products B.V. Bifeprunox for treating addiction
KR101125210B1 (ko) * 2009-09-11 2012-03-19 주식회사 대웅제약 아리피프라졸-벤토나이트-ａｅａ 혼성체, 이를 함유하는 약학 조성물 및 그 제조방법
US20110140304A1 (en) * 2009-12-10 2011-06-16 Molecular Imprints, Inc. Imprint lithography template
US8592427B2 (en) 2010-06-24 2013-11-26 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US8383663B2 (en) * 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
IL296695A (en) 2011-03-18 2022-11-01 Alkermes Pharma Ireland Ltd Pharmaceutical preparations containing sorbitan esters
CA2858787C (en) 2011-12-15 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of tertiary amine compounds
TW201332572A (zh) * 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
DK2814849T3 (da) 2012-02-15 2020-03-09 Cydex Pharmaceuticals Inc Fremgangsmåde til fremstilling af cyclodextrin-derivater
JP6333802B2 (ja) 2012-03-19 2018-05-30 アルカームス ファーマ アイルランド リミテッド ベンジルアルコールを含む医薬組成物
CA2867123C (en) 2012-03-19 2021-02-16 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising water-insoluble antipsychotic agents and glycerol esters
WO2013142198A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
KR101571670B1 (ko) 2012-08-08 2015-11-25 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제
NZ730571A (en) 2012-09-19 2018-12-21 Alkermes Pharma Ireland Ltd Pharmaceutical compositions having improved storage stability
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
GR1008186B (el) 2013-04-22 2014-05-08 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα περιεχον ενα ατυπο αντιψυχωσικο παραγοντα και μεθοδος για την παρασκευη αυτου
JP6203682B2 (ja) * 2013-07-10 2017-09-27 共和薬品工業株式会社 アリピプラゾール含有水性液剤
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US20150086408A1 (en) * 2013-09-26 2015-03-26 General Electric Company Method of manufacturing a component and thermal management process
EP3086793B1 (en) 2013-12-24 2022-05-11 Virginia Commonwealth University Use of oxygenated cholesterol sulfates (ocs) for the treatment of kidney dysfunction
GR1008442B (el) 2014-01-16 2015-03-05 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα περιεχον αριπιπραζολη ή αλας αυτης
EP3119399A4 (en) 2014-03-20 2017-09-27 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
CN105078910B (zh) * 2015-09-22 2018-05-22 成都欣捷高新技术开发有限公司 一种含有依匹哌唑的冻干口服制剂及其制备方法
US10780099B2 (en) 2015-10-16 2020-09-22 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
CN105616344A (zh) * 2016-01-06 2016-06-01 万全万特制药江苏有限公司 阿立哌唑注射液及其制备方法
AU2017305239C1 (en) * 2016-08-02 2022-08-18 Durect Corporation Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
CA3043979A1 (en) 2016-11-18 2018-05-24 Aicuris Anti-Infective Cures Gmbh Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
US11033506B2 (en) 2017-11-21 2021-06-15 Sekisui Chemical Co., Ltd. External skin preparation comprising a core-shell structure
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
JP2022543837A (ja) 2019-08-05 2022-10-14 マリナス ファーマシューティカルズ， インコーポレイテッド てんかん重積状態の治療に使用するためのガナキソロン
JP2023503928A (ja) 2019-12-06 2023-02-01 マリナス ファーマシューティカルズ， インコーポレイテッド 結節性硬化症の治療での使用のためのガナキソロン

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
JP2893175B2 (ja) * 1988-10-31 1999-05-17 大塚製薬株式会社 カルボスチリル誘導体
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神***病治療剤
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
IT1263831B (it) 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
JPH07165616A (ja) * 1993-12-09 1995-06-27 Hisamitsu Pharmaceut Co Inc シクロデキストリンの複合組成物及び複合化法
US5646131A (en) 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
IT1269578B (it) 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
JP4012994B2 (ja) 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
JPH10194996A (ja) 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物
GB9713149D0 (en) 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
SE0200301D0 (sv) * 2002-02-01 2002-02-01 Axon Biochemicals Bv Thio-carbostyril derivative
CA2495864C (en) * 2002-08-20 2011-09-27 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
KR20050071611A (ko) 2002-10-25 2005-07-07 화이자 프로덕츠 인코포레이티드 현탁액 형태의 아릴헤테로환 활성제의 저장 제형

Also Published As

Publication number Publication date
US20150328335A1 (en) 2015-11-19
CY1110331T1 (el) 2015-01-14
US20140235574A1 (en) 2014-08-21
HRP20050149A2 (en) 2005-10-31
US7550445B2 (en) 2009-06-23
ES2322953T3 (es) 2009-07-02
AR040887A1 (es) 2005-04-20
RU2005107471A (ru) 2005-09-10
JP4729306B2 (ja) 2011-07-20
KR101043866B1 (ko) 2011-06-22
CA2495864C (en) 2011-09-27
GEP20063996B (en) 2006-12-11
CN1674882A (zh) 2005-09-28
PL374798A1 (en) 2005-10-31
US20040077594A1 (en) 2004-04-22
MXPA05001865A (es) 2005-06-03
WO2004017897A2 (en) 2004-03-04
US8999952B2 (en) 2015-04-07
NZ537995A (en) 2007-11-30
TWI307626B (en) 2009-03-21
ATE428423T1 (de) 2009-05-15
PL212428B1 (pl) 2012-09-28
IS7701A (is) 2005-02-18
US20120053145A1 (en) 2012-03-01
EP1542668B1 (en) 2009-04-15
WO2004017897A3 (en) 2004-12-02
CA2495864A1 (en) 2004-03-04
MY140793A (en) 2010-01-15
EP1542668A4 (en) 2007-10-17
IS2878B (is) 2014-04-15
IL166623A0 (en) 2006-01-15
US20130045981A1 (en) 2013-02-21
UA79984C2 (en) 2007-08-10
RS20050118A (en) 2007-06-04
US20090186903A1 (en) 2009-07-23
US20110160224A1 (en) 2011-06-30
CN100335047C (zh) 2007-09-05
AU2003269965A1 (en) 2004-03-11
RU2342931C2 (ru) 2009-01-10
AR102101A2 (es) 2017-02-01
NO333458B1 (no) 2013-06-10
US7115587B2 (en) 2006-10-03
DE60327225D1 (de) 2009-05-28
EP1542668A2 (en) 2005-06-22
SI1542668T1 (sl) 2009-08-31
JP2006501240A (ja) 2006-01-12
US20060234979A1 (en) 2006-10-19
HRP20050149B1 (hr) 2014-09-12
AU2003269965B2 (en) 2008-02-21
PE20040895A1 (es) 2004-11-20
ZA200501064B (en) 2006-12-27
TW200405813A (en) 2004-04-16
IL166623A (en) 2011-07-31
KR20050040927A (ko) 2005-05-03
BR0313602A (pt) 2005-06-21
NO20050661L (no) 2005-03-16
PT1542668E (pt) 2009-06-09
DK1542668T3 (da) 2009-07-20

Similar Documents

Publication Publication Date Title
RS51903B (sr) Formulacija aripiprazol kompleksa i postupak
NO2014027I1 (no) Aripiprazol (preparat - krav 1 og 2 i patentet)
AU2002343557A1 (en) Substituted aryl 1,4-pyrazine derivatives
WO2004003120A3 (en) Ionic liquid based products and method of using the same
AU2003299585A1 (en) Water-soluble products and methods of making and using the same
AP2421A (en) Quinoline derivatives and their use as mycobacterial inhibitors.
AU2003259271A1 (en) Bipolar articles and related methods
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
AU2003270489A1 (en) 6-ARYL-IMIDAZO(1,2-a)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
AU2003252246A1 (en) Herbicide compositions and weedkilling method using the same
WO2002102586A3 (en) Cellulose-polymer composites and methods for manufacturing same
AU2003251529A1 (en) Planetarium and point light source for the use in same
ATE365748T1 (de) Polymer-konjugate von neublastin und methoden für deren verwendung
AU2002320844A1 (en) Online creation and management of enterprises
AU2002256347A1 (en) Compositions and methods for the identification of protein interactions in vertebrate cells
DE50310323D1 (de) Wässrige polyurethanzubereitungen
DE602004018320D1 (de) N-ä3-(3-substituierte pyrazoloä1,5-aüpyrimidin-7-yl)phenylü-sulfonamide, und zusammensetzungen, und damit in zusammenhang stehende verfahren
AU2003256215A1 (en) Method and probe for identifying bacterial virulence modifying agents, agents thus identified, and their use
WO2003066000A3 (en) Formulation comprising bioactive agents and method of using same
AU2003290538A1 (en) Substrates of n-end rule ubiquitylation and methods for measuring the ubiquitylation of these substrates
WO2006017440A3 (en) Cosmetic enhancement mirror
ITMI20021294A1 (it) Polisaccaridi batterici o-solfatati e loro uso
AU2003217392A1 (en) Methods for identifying targeting domains and methods and compositions comprising the same
AU2002951338A0 (en) Method and computer program for the management of tabletop wargame campaigns
AU2003226306A1 (en) Tapered furniture leg and method of making the same